<DOC>
	<DOCNO>NCT01808599</DOCNO>
	<brief_summary>Single arm phase II study Chlorambucil combination subcutaneous Rituximab follow maintenance therapy subcutaneous Rituximab patient histologically proven diagnosis CD20-positive marginal zone B-cell lymphoma MALT type arisen extranodal site , either de novo , relapse follow local therapy ( include surgery , radiotherapy antibiotic H. pylori-positive gastric lymphoma ) .</brief_summary>
	<brief_title>Phase II Study Chlorambucil Subcutaneous Rituximab Patients With Extranodal MALT Lymphoma</brief_title>
	<detailed_description>The study consist three part . In Part A ( induction phase I ) patient treat Chlorambucil 6 mg/m2 daily p.o 42 consecutive day ( week 1-6 ) combination intravenous Rituximab 375mg/m2 day 1 week 1 follow subcutaneous Rituximab 1400mg day 8 , 15 22 ( day 1 week 2 , 3 4 ) . After restaging ( CT scan perform week 7-8 , i.e . d42 d55 ) , respond patient ( CR , CRu , PR ) stable disease treat part B ( induction phase II ) . In part B , start d56 , ( month 3 ) patient receive Chlorambucil 6 mg/m2 daily p.o 14 consecutive day ( d1-14 ) every 28 day 4 cycle combination subcutaneous Rituximab 1400mg day 1 28-day cycle . After restaging ( CT scan perform end month 6 ) respond patient stable disease treat part C. In Part C ( maintenance phase ) patient treat subcutaneous Rituximab 1400mg every two month 2 year ( total 12 injection ) . During maintenance phase , CT scan perform every 12 month patient respond stable disease stay treatment total two year report .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>1 . Histologically proven diagnosis CD20positive marginal zone Bcell lymphoma MALT type either de novo , relapse follow local therapy ( include surgery , radiotherapy antibiotic H. pyloripositive gastric lymphoma ) arise extranodal site 1.1 The following patient gastric MALT Lymphoma enter : H. pylorinegative case , either de novo ( non pretreated ) relapse follow local therapy ( i.e. , surgery , radiotherapy antibiotic ) . H. pyloripositive case diagnosis , fail antibiotic therapy , include Patients clinical ( endoscopic ) histological evidence disease progression time post H. pylori eradication Stable disease persistent lymphoma ≥ 1 year post H. pylorus eradication Relapse ( without H. pylorus reinfection ) , remission Patients fail either first line antibiotic local treatment ( surgery radiotherapy ) 1.2 Similar consideration may apply patient ocular adnexal lymphoma treat antibiotic . 2 . Measurable evaluable disease . Measurable disease least two perpendicular dimension image scan define : lymph node nodal mass bidimensional measurement &gt; 1.5 cm long transverse diameter short diameter must measure &gt; 10 mm regardless long transverse diameter . 3 . Any stage ( Ann Arbor IIV ) ( see Appendix A ) 4 . Age ≥ 18 5 . Life expectancy least 1 year 6 . ECOG performance status 02 ( see Appendix B ) 7 . Adequate bone marrow function ( WBC &gt; 3.0x109/L , ANC &gt; 1.5x109/L , PLT &gt; 100x109/L ) , unless due lymphoma involvement 8 . Adequate kidney ( serum creatinine &lt; 1,5x upper normal ) liver function ( ASAT/ALAT &lt; 2,5 upper normal , total bilirubin &lt; 2,5x upper normal ) , unless due lymphoma involvement 9 . For woman childbearing potential : negative serum pregnancy test do within 7 day prior study drug administration within 14 day confirmatory urine pregnancy test within 7 day prior first study drug administration 10 . Fertile male female patient childbearing potential partner must use two form contraception study least 12 month last dose subcutaneous rituximab . For appropriate method contraception consider acceptable , see Appendix C. Should woman become pregnant suspect pregnant partner participate study 12 month study participation , patient inform treat physician immediately . Female patient childbearing potential defined follow : Premenopausal woman ( patient regular menstruation , patient menarche amenorrhea irregular cycle , patient use contraceptive method precludes withdrawal bleed Women tubal ligation Female patient may consider NOT childbearing potential following reason : The patient undergone total abdominal hysterectomy bilateral salpingooophorectomy bilateral oophorectomy The patient medically confirm menopausal ( menstrual period ) 24 consecutive month 11 . Ability understand willingness sign write informed consent document 1 . Evidence histologic transformation high grade lymphoma 2 . Prior diagnosis neoplasm within 5 year , except cervical intraepithelial neoplasia type 1 ( CIN1 ) localize nonmelanomatous skin cancer 3 . Prior chemotherapy 4 . Prior immunotherapy antiCD20 monoclonal antibody 5 . Prior radiotherapy last 6 week 6 . Use corticosteroids last 28 day , unless prednisone chronically administer dose &lt; 20 mg/day indication lymphoma lymphomarelated symptom 7 . Evidence clinically significant cardiac disease , define history symptomatic ventricular arrhythmia , congestive heart failure myocardial infarction within 12 month study entry 8 . Evidence symptomatic central nervous system ( CNS ) disease 9 . Evidence active opportunistic infection 10 . Known HIV infection 11 . Positive serology Hepatitis B ( HB ) define positive test HBsAg . In addition , negative HBsAg HBcAb positive ( regardless HBsAb status ) , HBV DNA test perform positive subject exclude 12 . Positive serology hepatitis C ( HC ) define positive test HCAb , confirm HC RIBA immunoblot assay sample . 13 . Pregnant lactating status 14 . Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial 15 . Fertile men woman childbearing potential agree use highly effective measure contraception ( oral contraceptive , intrauterine device barrier method contraception conjunction spermicidal jelly surgically sterile ) throughout study least 12 month last dose subcutaneous rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>